Skip to content

The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment, Sixth Edition

Edited by Kathleen T. Brady, M.D., Ph.D., Frances R. Levin, M.D., Marc Galanter, M.D., and Herbert D. Kleber, M.D.

  • 2021
  • 912 Pages
  • ISBN 978-1-61537-221-8
  • Item #37221

View Pricing

List Price

APA Members

20% off

APA Resident-Fellow Members

25% off

Buying In Canada or Europe?


A robust revision, including many entirely new chapters addressing policy, the latest treatment approaches, and special topics, the Sixth Edition of The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment offers a comprehensive and compelling review of this ever-evolving field. New sections address important topics that have gained prominence or become the focus of increased research attention since the Fifth Edition was released. For example, substance use and other psychiatric disorders often co-occur, and the resulting dual disorder is frequently associated with greater symptom severity and worse long-term prognosis than either disorder alone. Accordingly, the section on psychiatric comorbidity covers the epidemiology, assessment, and treatment of substance use disorders (SUDs) that co-occur with psychotic, mood, anxiety, eating, attention-deficit/hyperactivity, or trauma-related disorders. The section devoted to special populations has been revamped, and the topics have been thoroughly updated, some now covered by new contributors and others completely new to this edition. SUDs among women (including perinatal issues), adolescents, patients with chronic pain, sexual and gender minority populations, and older adults are addressed in detailed chapters, as are behavioral addictive disorders and cross-cultural aspects of substance-related and addictive disorders. Finally, the editors have included a section devoted to critically important topics in public health, including the U.S. opioid epidemic, cannabis policy and use, HIV/AIDS and hepatitis C, nicotine and public health, and the prevention of SUDs.

New or noteworthy coverage includes the following:

  • A chapter devoted to the legal and practical aspects of addiction in the occupational sphere, designed for clinicians who treat people with SUDs and/or develop workplace testing programs, employee assistance programs, and occupational drug/alcohol policies for these workers.
  • A chapter that surveys the growing literature supporting the use of mindfulness, exercise, and other mind and body practices (e.g., yoga, acupuncture, tai chi) as complements or alternatives to standard SUD treatment models.
  • A chapter devoted to hallucinogens, which clarifies their actions, psychoactive effects, historical uses, potential therapeutic benefits, and neural mechanisms, and both identifies their risks and seeks to dispel some of the misconceptions that have continued to surround them.
  • A suite of chapters devoted to cannabis, encompassing a review of its neurobiology and history, a survey of effective treatment approaches and harm-reduction strategies for cannabis use disorder, and a consideration of evolving public policy around cannabis use.
  • A trio of chapters devoted to nicotine and tobacco, encompassing a review of neurobiology, a survey of clinical assessment tools, a summary of the research base for effective treatments for tobacco use disorder, and a consideration of public health policy and interventions regarding tobacco use.

Evidence-based, down to earth, and meticulously edited, the new Sixth Edition of The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment is an essential resource for clinicians who treat SUDs in a variety of settings—from examining rooms to emergency departments, and from hospitals to recovery facilities.


  • Contributors
  • Part I: The Basis of Substance-Related and Addictive Disorders

  • Chapter 1. Neurocircuitry of Addiction
  • Chapter 2. Genetics and Epigenetics of Addiction
  • Chapter 3. Epidemiology of Addiction
  • Chapter 4. Substance Use Disorder Diagnoses in DSM-5
  • Part II: Assessment and Treatment

  • Chapter 5. Assessment
  • Chapter 6. Screening and Brief Intervention
  • Chapter 7. Treating Addiction Like a Chronic Illness: A Practical Clinical Model
  • Part III: Specific Drugs of Abuse: Neurobiology and Pharmacotherapy

  • Chapter 8. Neurobiology of Alcohol
  • Chapter 9. Treatment of Alcohol-Related Disorders
  • Chapter 10. Neurobiology of Stimulants
  • Chapter 11. Treatment of Stimulant-Related Disorders
  • Chapter 12. Neurobiology of Opioids
  • Chapter 13. Methadone and Buprenorphine Maintenance Treatment of Opioid-Related Disorders
  • Chapter 14. Opioid Antagonist Treatment of Opioid-Related Disorders
  • Chapter 15. Neurobiology and Treatment of Hallucinogen Use Disorder
  • Chapter 16. Neurobiology of Marijuana
  • Chapter 17. Treatment of Cannabis-Related Disorders
  • Chapter 18. Neurobiology of Nicotine and Tobacco
  • Chapter 19. Treatment of Tobacco-Related Disorders
  • Chapter 20. Neurobiology and Treatment of Sedative-, Hypnotic-, and Anxiolytic-Related Disorders
  • Chapter 21. Neurobiology and Treatment of Anabolic-Androgenic Steroid–Related Disorders
  • Part IV: Nonpharmacotherapeutic Treatment Modalities

  • Chapter 22. Psychodynamic Psychotherapy
  • Chapter 23. Cognitive-Behavioral Therapy
  • Chapter 24. Contingency Management
  • Chapter 25. Motivational Enhancement
  • Chapter 26. Alcoholics Anonymous and Twelve-Step Facilitation
  • Chapter 27. Family Therapy
  • Chapter 28. Network Therapy
  • Chapter 29. Digitally Delivered Therapies
  • Chapter 30. Mindfulness, Exercise, and Other Alternative Approaches
  • Part V: Public Health Issues

  • Chapter 31. The U.S. Opioid Crisis
  • Chapter 32. Cannabis Policy and Use
  • Chapter 33. HIV/AIDS and Hepatitis C
  • Chapter 34. Public Health and Nicotine
  • Chapter 35. Prevention of Substance Use Disorders
  • Part VI: Special Populations

  • Chapter 36. Substance-Related Disorders in Women
  • Chapter 37. Substance-Related Disorders in Adolescents
  • Chapter 38. Substance-Related Disorders in Patients With Chronic Pain
  • Chapter 39. Substance Use and Related Disorders in Sexual and Gender Minority Populations
  • Chapter 40. Cross-Cultural Aspects of Substance-Related and Addictive Disorders
  • Chapter 41. Substance-Related Disorders in Older Adults
  • Chapter 42. Behavioral Addictive Disorders
  • Part VII: Psychiatric Comorbidity in Substance-Related Disorders

  • Chapter 43. Epidemiology of Co-Occurring Psychiatric and Substance Use Disorders
  • Chapter 44. Mood Disorders
  • Chapter 45. Anxiety Disorders
  • Chapter 46. Eating Disorders
  • Chapter 47. Attention-Deficit/Hyperactivity Disorder
  • Chapter 48. Trauma- and Stressor-Related Disorders
  • Chapter 49. Schizophrenia Spectrum and Other Psychotic Disorders
  • Part VIII: Special Topics

  • Chapter 50. Testing for Substances of Abuse
  • Chapter 51. Forensic Addiction Psychiatry
  • Chapter 52. Medical Education on Addiction
  • Chapter 53. Addiction in the Workplace
  • Index


    Elie G. Aoun, M.D.
    Sudie Back, Ph.D.
    Kelly S. Barth, D.O.
    Neal L. Benowitz, M.D.
    Carlos Blanco, M.D., Ph.D., M.S.
    Ron Borland, Ph.D., FASSA
    Sarah Bowen, Ph.D.
    David Braak, M.D. Candidate
    Kathleen T. Brady, M.D., Ph.D.
    Alyssa Braxton, M.D.
    Timothy D. Brewerton, M.D.
    Christina Brezing, M.D.
    Mary F. Brunette, M.D.
    Alan J. Budney, Ph.D.
    Michael Capata, M.D.
    Kenneth M. Carpenter, Ph.D.
    Kathleen M. Carroll, Ph.D.
    Vamsee Chaguturu, M.D.
    Katrina E. Champion, Ph.D.
    Sandra D. Comer, Ph.D.
    Wilson M. Compton, M.D., M.P.E.
    Nina Cooperman, Psy.D.
    Linda B. Cottler, Ph.D., M.P.H., FACE
    K. Michael Cummings, Ph.D., M.P.H.
    Elias Dakwar, M.D.
    Jeffrey J. DeVido, M.D., M.T.S., FASAM
    Elise E. DeVito, Ph.D.
    Ellen L. Edens, M.D., M.P.E., M.A.
    Nady el-Guebaly, M.D., D.Psych., D.P.H.
    Skye Fitzpatrick, Ph.D.
    Timothy Fong, M.D.
    Marc Galanter, M.D.
    Joel Gelernter, M.D.
    David A. Gorelick, M.D., Ph.D., DLFAPA, FASAM
    Kevin M. Gray, M.D.
    Alan I. Green, M.D.
    Shelly F. Greenfield, M.D., M.P.H.
    Noah R. Gubner, Ph.D.
    Constance Guille, M.D.
    Karen J. Hartwell, M.D.
    Deborah S. Hasin, Ph.D.
    Markus Heilig, M.D., Ph.D.
    Grace Hennessy, M.D.
    Denise A. Hien, Ph.D.
    Elizabeth F. Howell, M.D., M.S., DLFAPA, DFASAM
    Amber Jarnecke, Ph.D.
    Christopher M. Jones, Pharm.D., Dr.P.H.
    Jennifer L. Jones, M.D.
    Jermaine D. Jones, Ph.D.
    Tamar A. Kaminski, B.S.
    Gen Kanayama, M.D., Ph.D.
    Edward J. Khantzian, M.D.
    Jeremy D. Kidd, M.D., M.P.H.
    Therese K. Killeen, Ph.D., A.P.R.N.
    Brian D. Kiluk, Ph.D.
    Hyoun S. Kim, M.A.
    Jungjin Kim, M.D.
    Herbert D. Kleber, M.D.
    George F. Koob, Ph.D.
    Thomas R. Kosten, M.D.
    Farren R.R. Larson, M.A.
    Cameron S. Laue, B.A.
    Charles J. Levin, B.A.
    Frances R. Levin, M.D.
    Sarah E. Lord, Ph.D.
    Robert Malcolm, M.D.
    Lisa A. Marsch, Ph.D.
    Jenna L. McCauley, Ph.D.
    A. Thomas McLellan, Ph.D.
    Aimee McRae-Clark, Pharm.D.
    Souparno Mitra, M.D.
    Larissa J. Mooney, M.D.
    Mudassir Mumtaz, B.S.
    Hugh Myrick, M.D.
    Nicola C. Newton, Ph.D.
    Andrea Norcini Pala, Ph.D.
    Sonya Norman, Ph.D.
    Edward Nunes, M.D.
    Mayumi Okuda, M.D.
    Nancy Petry, Ph.D.
    Renato Polimanti, Ph.D.
    Harrison G. Pope Jr., M.D.
    Katherine Pruzan, Psy.D.
    Richard A. Rawson, Ph.D.
    Robert H. Remien, Ph.D.
    Richard K. Ries, M.D.
    Amanda T. Roten, M.D.
    Maria Alejandra Gallo Ruiz, M.D.
    Gregory Sahlem, M.D.
    Richard Saitz, M.D., M.P.H., FACP, DFASAM
    Kristen Schmidt, M.D.
    Jeffrey D. Schulden, M.D.
    Elizabeth K.C. Schwartz, M.D., Ph.D.
    Katherine M. Seavey, B.A.
    Brian Sherman, Ph.D.
    Matisyahu Shulman, M.D.
    Allison J. Smith, M.D.
    Nathan D.L. Smith, A.L.M.
    Mehmet Sofuoglu, M.D., Ph.D.
    Rainer Spanagel, Ph.D.
    Peter Steinglass, M.D.
    Maxine L. Stitzer, Ph.D.
    Kenneth B. Stoller, M.D.
    Eric C. Strain, M.D.
    Elizabeth Straus, Ph.D.
    Maria A. Sullivan, M.D., Ph.D.
    Mary M. Sweeney, Ph.D.
    Maree Teesson, Ph.D.
    Amy VandenBerg, Pharm.D., BCPP
    Nora D. Volkow, M.D.
    Jonathan M. Wai, M.D.
    Robert Werner, M.D.
    Laurence M. Westreich, M.D.
    Timothy E. Wilens, M.D.
    Arthur Robin Williams, M.D., M.B.E.
    Jill M. Williams, M.D.
    Adam D. Wilson, M.S.
    Tara M. Wright, M.D.

About the Authors

Kathleen T. Brady, M.D., Ph.D., is Distinguished University Professor and Vice President for Research in the Department of Psychiatry and Behavioral Sciences, Clinical Neuroscience Division, as well as Director of the South Carolina Clinical and Translational Research Institute, at the Medical University of South Carolina, in Charleston, South Carolina.

Frances R. Levin, M.D., is Kennedy-Leavy Professor of Psychiatry at Columbia University Medical Center, and Chief of the Division on Substance Use Disorders at the New York State Psychiatric Institute in New York, New York.

Marc Galanter, M.D., is Professor of Psychiatry and Director of the Division of Alcoholism and Drug Abuse at New York University School of Medicine in New York, New York.

Herbert D. Kleber, M.D., was Professor of Psychiatry and Director of the Division on Substance Abuse at Columbia University in New York, New York.

Related Products

Become an APA Member
Join Now